Interstitial lung disease in systemic sclerosis

Presse Medicale

Volumn 43, Issue 10, 2014, Pages e329-e343

  Wells, Athol U ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANTIBODY RESPONSE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; GENETIC ASSOCIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS; INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SLEROSIS; LUNG FUNCTION TEST; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT MONITORING; PREDICTIVE VALUE; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT SURVEY; SYSTEMIC SCLEROSIS; THORACIC HIGH RESOLUTION COMPUTED TOMOGRAPHY; COMPLICATION; DISEASE COURSE; FORECASTING; LUNG DISEASES, INTERSTITIAL; SEVERITY OF ILLNESS INDEX;

DISEASE PROGRESSION; FORECASTING; HUMANS; LUNG DISEASES, INTERSTITIAL; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 84908398611     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.08.002     Document Type: Short Survey

References (104)

1. Chifflot H., Fautzi B., Sordet C., et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008, 37:223-235.
2. American Thoracic Society/European Respiratory Society International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002, 165:277-304.
3. Tyndal A.J., Banert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
4. Steen V.D., Conte C., Owens G.R., Medsger T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283-1289.
5. Mayes M.D., Lacey J.V., Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
6. Reveille J.D. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 2003, 5:160-167.
7. D'Angelo W.A., Fries J.F., Masi A.T., Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428-440.
8. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581-1586.
9. Launay D., Remy-Jardin M., Michon-Pasturel U., et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006, 33:1789-1801.
10. De Santis M., Bosello S., La Torre G., et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005, 17(6):96.
11. Desai S.R., Veeraraghavan S., Hansell D.M., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004, 232:560-567.
12. Wells A.U., Cullinan P., Hansell D.M., et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994, 149:1583-1590.
13. Daniil Z.D., Gilchrist F.C., Nicholson A.G., et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999, 160:899-905.
14. Kocheril S.V., Appleton B.E., Somers E.C., et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005, 53:549-557.
15. Tashkin D.P., Elashoff R., Clements P.J., Scleroderma Lung Study Research Group, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
16. Goh N.S., Desai S.R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
17. Walker U.A., Tyndall A., Czirják L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and research group database. Ann Rheum Dis 2007, 66:754-763.
18. Czömpöly T., Simon D., Czirják L., Németh P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-696.
19. Briggs D.C., Vaughan R.W., Welsh K.I., et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991, 14(338):661-662.
20. Kuwana M., Kaburaki J., Mimori T., Kawakami Y., Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000, 43:1074-1084.
21. Hu P.Q., Fertig N., Medsger T.A., Wright T.M. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003, 48:1363-1373.
22. Reveille J.D., Solomon D.H., American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines Evidence-based guidelines for the use of immunologic tests: anticentromere. Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412.
23. Assassi S., Sharif R., Lasky R.E., GENISOS Study Group, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010, 12:R166.
24. Gilchrist F.C., Bunn C., Foley P.J., et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001, 2:76-81.
25. Feghali-Bostwick C., Medsger T.A., Wright T.M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956-1963.
26. Zhou X., Tan F.K., Wang N., et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003, 48:2585-2592.
27. Fonseca C., Lindahl G.E., Ponticos M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007, 357:1210-1220.
28. Bossini-Castillo L., Simeon C.P., Beretta L., et al. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther 2012, 14:R85.
29. Gorlova, Martin J.E., Rueda B., et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011, 7:e1002178.
30. Cénit M.C., Simeon C.P., VonK M.C., et al. Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012, 39:2294-2302.
31. Dieudé P., Guedj M., Truchetet M.E., et al. Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of co-stimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum 2011, 63:1097-1105.
32. Allanore Y., Dieude P., Boileau C. Genetic background of systemic sclerosis: autoimmune genese take centre stage. Rheumatology (Oxford) 2010, 49:203-210.
33. Sumita Y., Sugiura T., Kawaguchi Y., et al. Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease. Rheumatology (Oxford) 2008, 47:289-291.
34. Kawaguchi Y., Tochimoto A., Ichikawa N., et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum 2003, 48:186-192.
35. Beretta L., Bertolotti F., Cappiello F., et al. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. Hum Immunol 2007, 68:603-609.
36. Maurer B., Reich N., Junegel A., et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012, 71:1382-1387.
37. Hsu E., Shi H., Jordan R.M., Lyons-Weiler J., Pilewski J.M., Feghali-Bostwick C.A. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011, 63:783-794.
38. Peljto A.L., Steele M.P., Fingerlin T.E., et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012, 142:1584-1588.
39. Hant F.N., Ludwicka-Bradley A., Wang H.J., et al. Scleroderma Lung Study Research Group Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009, 36:773-780.
40. Goh N.S., Desai S.R., Anagnostopoulos C., et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 2011, 38:184-190.
41. Denton C.P., Lindahl G.E., Khan K., et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II TGF-beta receptor. J Biol Chem 2005, 280:16053-16065.
42. Denton C.P., Zheng B., Evans L.A., et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta receptor leads to paradoxical activation of TGFbeta signalling pathways with fibrosis in transgenic mice. J Biol Chem 2003, 278:25109-25119.
43. Hoyles R.K., Khan K., Shiwen X., et al. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum 2008, 58:1175-1188.
44. Christmann R.B., Wells A.U., Capelozzi V.L., Silver R.M. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010, 40:241-249.
45. Walker N., Badri L., Wetlauffer S., et al. Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts. Am J Pathol 2011, 178:2461-2469.
46. Borie R., Quesnel C., Phin S., et al. Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PLoS ONE 2013, 8:e53736.
47. Sonnylal S., Denton C.P., Zheng B., et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007, 56:334-344.
48. Hoyles R.K., Derrett-Smith E.C., Khan K., et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor receptor. Am J Respir Crit Care Med 2011, 183:249-261.
49. Derrett-Smith E.C., Dooley A., Gilbane A.J., et al. Endothelial injury in a TGFbeta dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013, 65:2928-2939.
50. Nihtyanova S.I., Denton C.P. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010, 6:112-116.
51. Giovannetti A., Rosato E., Renzi C., et al. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 2010, 137:122-133.
52. Pechkovsky D.V., Prasse A., Kollert F., et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 2010, 137:89-101.
53. Beirne P., Pantelidis P., Charles P., et al. Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J 2009, 34:1376-1382.
54. Wells A.U. Pulmonary function tests in connective tissue disease (review). Semin Respir Crit Care Med 2007, 28:379-388.
55. Douglas W.W., Tazelaar H.D., Hartman T.E., et al. Polymyositis-dermatomyositis associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164:1182-1185.
56. Wells A.U., Hansell D.M., Corrin B., Harrison N.K., Goldstraw P., Black C.M., et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992, 47:738-742.
57. Remy-Jardin M., Giraud F., Remy J., Copin M.C., Gosselin B., Duhamel A. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993, 189:693-698.
58. Wells A.U., Rubens M.B., du Bois R.M., Hansell D.M. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 1993, 161:1159-1165.
59. Shah R.M., Jimenez S., Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007, 22:120-124.
60. Keogh B.A., Crystal R.G. Pulmonary function testing in interstitial pulmonary disease. What does it tell us?. Chest 1980, 78:856-964.
61. Peters-Golden M., Wise R.A., Hochberg M.C., Stevens M.B., Wigley F.M. Carbon monoxide diffusing capacity as a predictor of outcome in systemic sclerosis. Am J Med 1984, 77:1027-1034.
62. Morgan C., Knight C., Lunt M., Black C.M., Silman A.J. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003, 62:97-99.
63. Gibson G.J. "Clinical tests of respiratory function" 1996, 223-224. Chappell and Hall, London.
64. Wells A.U., Hansell D.M., Rubens M.B., et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997, 40:1229-1236.
65. Latsi P.I., Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003, 15:748-755.
66. Steen V. Predictors of end stage lung disease in systemic sclerosis (editorial). Ann Rheum Dis 2003, 62:97-99.
67. Wells A.U., Hansell D.M., Rubens M.B., Cailes J.B., Black C.M., du Bois R.M. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997, 155:1657-1664.
68. Cosgrove G.P., Brown K.K., Schiemann W.P., Seris A.E., Parr J.E., Geraci M.W. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004, 170:242-251.
69. Wallaert B., Dugas M., Dansin E., et al. Subclinical alveolitis in immunological systemic disorders. Transition between health and disease?. Eur Respir J 1990, 3:1206-1216.
70. Silver R.M., Miller K.S., Kinsella M.B., et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990, 88:470-476.
71. Witt C., Borges A.C., John M., et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis. Broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999, 58:635-640.
72. Wells A.U., Hansell D.M., Haslam P.L., et al. Bronchoalveolar lavage cellularity: Lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med 1998, 157:1474-1482.
73. Goh N.S., Veeraraghavan S., Desai S.R., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007, 56:2005-2012.
74. Strange C., Bolster M.B., Roth M.D., et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008, 177:91-98.
75. Moore O.A., Goh N., Corte T., et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013, 52:155-160.
76. Ohnishi H., Yokoyama A., Kondo K., et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002, 165:378-381.
77. Hasegawa M., Fujimoto M., Hamaguchi Y., et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol 2011, 38:877-884.
78. Bonella F., Volpe A., Caramaschi P., et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:27-33.
79. De Lauretis A., Sestini P., Pantelidis P., et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013, 40:435-446.
80. Kim H.J., Li G., Gjertson D., et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicentre study. Acad Radiol 2008, 15:1004-1016.
81. White B., Moore W.C., Wigley F.M., Xiao H.Q., Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
82. Nannini C., West C.P., Erwin P.J., Matteson E.L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.
83. Poormoghim H., Moradi Lakeh M., Mohammadipour M., Sodagari F., Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis (review). N Rheumatol Int 2012, 32:2431-2444.
84. Hoyles R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
85. Seibold J.R., Denton C.P., Furst D.E., et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010, 62:2101-2108.
86. Jim H.J., Brown M.S., Elashoff R., et al. Quantitative texture-based assessment of one year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011, 21:2455-2465.
87. Kowal-Bielecka O., Landewe R., Avouac J., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
88. Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176:1026-1034.
89. Haubitz M., Schellong S., Gobel U., et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998, 41:1835-1844.
90. Nihtyanova S.I., Brough G.M., Black C.M., Denton C.P. Mycophenolate Mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 2007, 46:442-445.
91. Fischer A., Brown K.K., du Bois R.M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013, 40:640-646.
92. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that could precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
93. DeMarco P.J., Weisman M.H., Seibold J.R., et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002, 46:2983-2989.
94. Burt R.K., Shah S.J., Dill K., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011, 378:498-506.
95. Nash R.A., McSweeney P.A., Crofford L.J., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388-1396.
96. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010, 49:271-280.
97. Daoussis D., Liossis S.N., Tsamandas A.C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012, 30:S17-S22.
98. Sem M., Molberg O., Lund M.B., Gran J.T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009, 48:968-971.
99. Keir G.J., Maher T.M., Hansell D.M., et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012, 40:641-648.
100. Keir G.J., Maher T.M., Ming D., et al. Rituximab in severe treatment-refractory interstitial lung disease. Respirology 2014, 19:353-359.
101. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
102. King T.E., Bradford W.Z., Castro-Bernardini S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
103. Richeldi L., du Bois R.M., Raghu G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
104. Khanna D., Brown K.K., Clements P.J., et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials (review). Clin Exp Rheumatol 2010, 28:S55-S62.